ELMUSTINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H10ClN3O3
Molecular Weight	195.604
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCNC(=O)N(CCCl)N=O

InChI

InChIKey=YJZJEQBSODVMTH-UHFFFAOYSA-N

InChI=1S/C5H10ClN3O3/c6-1-3-9(8-12)5(11)7-2-4-10/h10H,1-4H2,(H,7,11)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3536942 | https://adisinsight.springer.com/drugs/800000840 | https://www.ncbi.nlm.nih.gov/pubmed/3066853 | https://www.ncbi.nlm.nih.gov/pubmed/2385341 | https://www.ncbi.nlm.nih.gov/pubmed/2193122

Elmustine (1-(2-hydroxyethyl)3-(2-chloroethyl)-3-nitrosourea or HECNU) is an alkylating agent with antineoplastic properties. Elmustine is monofunctional and bifunctional alkylating agent that form, in a quantitatively minor reaction, DNA-DNA crosslinks. In vitro, by far the most abundant alkylation products of DNA are those resulting from 2-hydroxyethylation. Elmustine is especially highly active against intracerebrally implanted tumors. It was in Phase II clinical trials for the treatment of glioma. Elmustine development has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Interdependent regulation of insulin receptor kinase activity by ADP and hydrogen peroxide.	2005-02-04	15563471

Sample Use Guides

In Vivo Use Guide

Phase II study: forty adults with recurring brain gliomas were treated with elmustine 130 mg/m2, given i.v. every 5 to 6 weeks (mean 5.4) and corticosteroids

Route of Administration: Other

Name

Type

Language

ELMUSTINE

Official Name

English

NSC-294895

Preferred Name

English

ELMUSTINE [MART.]

Common Name

English

elmustine [INN]

Common Name

English

1-(2-CHLOROETHYL)-3-(2-HYDROXYETHYL)-1-NITROSOUREA

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C699